Dr. Rao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10833 Le Conte Ave
Los Angeles, CA 90095Phone+1 310-794-8285
Summary
- Dinesh S. Rao received a B.S. summa cum laude in Biochemistry and an M.D. from Case Western Reserve University, Cleveland, USA. During this time he developed a deep interest in the pathogenesis of cancer, completing several projects in cancer research during medical school, and went on to a research fellowship at the University of Michigan. There, he made a seminal discovery implicating clathrin mediated trafficking of growth factor receptor tyrosine kinases in the pathogenesis of oncogenic transformation. He then combined clinical training in the pathology of hematologic diseases with further research training in the laboratory of Nobel laureate David Baltimore at Caltech. His research came to focus on post transcriptional mechanisms of gene regulation in hematologic development, immunity, and cancer, and resulted in several high-impact publications in well-regarded journals. He combines running a vibrant research laboratory with a busy diagnostic service in leukemia and lymphoma pathology.
Clinical Expertise
- Leukemia, Lymphoma
Education & Training
- California Institute of TechnologyPh.D., 2010
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematopathology, 2005 - 2006
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pathology-Anatomic and Clinical, 2003 - 2005
- University of Michigan Medical CenterPost-Doctoral Fellowship, 2000 - 2003
- Case Western Reserve University School of MedicineClass of 2000
- Case Western Reserve UniversityB.S., Biochemistry, Summa Cum Laude, 1995
Certifications & Licensure
- CA State Medical License 2004 - 2026
- American Board of Pathology Anatomic Pathology
- American Board of Pathology Hematopathology
Awards, Honors, & Recognition
- Harland G. Wood Prize, Best Undergraduate student in Biochemistry Case Western Reserve University, 1995
- Phi Beta Kappa Case Western Reserve University, 1994
- The Irving Feintech Family Foundation Research Award Tower Cancer Foundation, 2011
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsEnvelope protein-specific B cell receptors direct lentiviral vector tropism in vivo.Kari-Ann Takano, Anita A L Wong, Rebecca Brown, Kathy Situ, Bernadette Anne Chua
Molecular Therapy. 2024-05-01 - 5 citationsTargeting IGF2BP3 enhances antileukemic effects of menin-MLL inhibition in MLL-AF4 leukemia.Tasha L Lin, Amit K Jaiswal, Alexander J Ritter, Jenna Reppas, Tiffany M Tran
Blood Advances. 2024-01-23 - Small molecule inhibition of RNA binding proteins in haematologic cancer.Amit K Jaiswal, Michelle L Thaxton, Georgia M Scherer, Jacob P Sorrentino, Neil K Garg
RNA Biology. 2024-01-01
Journal Articles
- "MicroRNA-146a acts as a guardian of the quality and longevity of hematopoietic stem cells in mice"Zhao JL, Rao DS, O'Connell RM, Garcia-Flores Y, Baltimore D, eLife, 5/21/2013
- "A case of pediatric B-Lymphoblastic leukemia presenting with a t(9;12)(p24;q112) involving JAK2 and concomitant MLL rearrangement with apparent insertion at 6q27"Tirado CA, Shabsovich D, Denicola M, Rao D, Yang L, Garcia R, Rao N, Biomark Res, 1/1/2013
- "The CD44(high) Tumorigenic Subsets in Lung Cancer Biospecimens Are Enriched for Low miR-34a Expression"Basak SK, Veena MS, Oh S, Lai C, Vangala S, Elashoff D, Fishbein MC, Sharma S, Rao NP, Rao D, Phan R, Srivatsan ES, Batra RK, PLos One, 1/1/2013
- Join now to see all
Press Mentions
- ASH: Gene Therapy for Rare Genetic Disorder, Molecular Insights into Leukemia Growth and MoreDecember 2nd, 2024
Grant Support
- Protein-RNA interactions in cancerNIH/NCI2021–2026
- Novel methods to inhibit cancer stem cellsCalifornia Institute of Regenerative Medicine2022–2024
- Pathogenetic roles of USO1 in leukemogenesisNIH/NCI2021–2023
- Pathogenetic mechanisms of RNA binding protein IGF2BP3 in leukemogenesisAmerican Society of Hematology2020–2022
- Targeting RNA binding proteins in B-cell malignancyMargaret E. Early Medical Research Trust2017–2019
- RNA-binding proteins in the control of B-cell developmentNIH/NIAID2017–2019
- Unraveling the Function of RNA-Binding proteins in B-lymphoblastic LeukemiaNIH/NCI2016–2018
- Characterizing tumor suppressive functions of microRNAs in B-cell neoplasiaNIH/NCI2013–2017
- Function of non-coding RNA, MALAT1, in B-cell Development and LymphomaNIH/NCI2014–2015
- Role of B-cell oncogenes and miR-34 in B-cell development and lymphomagenesisNIH/NCI2009–2014
Committees
- Member, NCCN Guidelines Panel, Acute Myeloid Leukemia 2020 - Present
- Regular Member, NCI-I Study Section, NIH/NCI 2019 - Present
- Founding Member, Experimental Hematology Committee, Society for Hematopathology 2019 - Present
- Chair, Scientific Committee on Epigenetics and Genomics 2024 - 2024
- Vice Chair, Scientific Committee on Epigenetics and Genomics, American Society of Hematology 2023 - 2023
- Member, Scientific Committee on Epigenetics and Genomics, American Society of Hematology 2019 - 2022
Professional Memberships
- Member
- Fellow
- Member
- Member
- Society for HematopathologyMember
- International Society for Experimental HematologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: